EVE Health Group (ASX: EVE) has prescribed its Dyspro cannabinoid-based gummy for the treatment of dysmenorrhoea and endometriosis to Australian patients for the first time.
EVE issued the drug under the Therapeutic Goods Administration’s Special Access Scheme, marking the company’s transition from production and distribution to real-world patient access.
The milestone follows the company’s successful completion of GMP manufacture and distribution, continuing EVE’s commercial rollout.
Broader Distribution Channels
EVE is progressing new partnerships to broaden its prescription and distribution channels, with the aim of scaling patient access and supporting future export opportunities.
The company is also developing additional practitioner education initiatives to strengthen awareness and adoption across clinical networks, holding the first in-clinic seminar last week to demonstrate the therapeutic benefits of Dyspro and provide practical prescribing guidance.
Prescription of Dyspro comes in parallel with the launch of the Reclaim My Cycle online community platform that helps women manage dysmenorrhoea and endometriosis, and provide healthcare practitioners with up-to-date clinical resources.
The platform aims to support consumer engagement and clinical adoption, creating a bridge between awareness, prescription, and treatment outcomes.
Meaningful Relief to Women
EVE chair Rod Hannington said the first prescriptions were a critical development.
“The first patient prescriptions of Dyspro mark an important milestone in our mission to bring meaningful relief to women living with painful menstrual symptoms,” he said.
“Moving from manufacture and distribution to real-world use demonstrates the impact this product can have, and we are proud to support this launch with education and community resources through Reclaim My Cycle.”
Health and Financial Impact
Dysmenorrhoea affects more than 70% of Australian women of reproductive age and can have a significant impact on daily life, productivity and well-being.
In severe cases, symptoms are linked to endometriosis, a chronic condition that affects up to 14% of reproductive-age women.
Research estimates the economic burden of dysmenorrhoea and endometriosis in Australia at approximately $14.2 billion, largely through lost productivity.
The company is confident Reclaim My Cycle will give women, families, and clinicians access to credible, science-led resources at the same time that Dyspro is available on prescription.
